Comment from Biotechnology Innovation Organization (BIO)

Summary: The Biotechnology Innovation Organization (BIO), representing biotechnology companies and academic institutions, supports the FDA's draft guidance on using AI for regulatory decision-making. They advocate for a risk-based approach, requesting specific clarifications on data independence, global alignment with other health authorities, and the distinction between minor and major model changes.